Podcasts about mfs

Today's guests are Morningstar's Brian Moriarty and Jack Shannon. Brian is a principal, fixed-income strategies, for Morningstar. Before assuming his current role in 2015, Brian was a client solutions consultant for Morningstar Office, a practice and portfolio management system for independent financial advisors. Before joining Morningstar in 2013, he was a research assistant for DePaul University's religious studies department. Brian holds a bachelor's degree in political science from Michigan State University and a bachelor's degree in Islamic world studies from DePaul University. Jack Shannon is a principal, equity strategies, for Morningstar. He focuses on actively managed equity strategies and is the lead analyst for MFS and Artisan Partners, among other firms. Before joining Morningstar in 2020, Jack worked in commercial banking and was a consultant providing subject-matter expertise on complex financial litigation. Jack holds a bachelor's degree in economics and history from James Madison University. He also holds a master's of business administration in investments and corporate finance from the University of Notre Dame's Mendoza College of Business. Episode Highlights 00:02:06 What are Private Markets, and What Investment Opportunities Do They Provide? 00:03:13 Do Semiliquid Funds Provide Easier Access to Private Markets? 00:05:57 Applying Morningstar Processes to Evaluate Private Markets 00:09:50 Managing Liquidity in Private Market Investments 00:18:48 Valuation and Transparency: Putting Private Assets Under the Microscope 00:24:07 Payment in Kind as a Valuation Concern 00:28:02 Public vs. Private Markets: Understanding Risk, Language, and Infrastructure Differences 00:39:28 Building Methodology to Explain Private Asset Fees and Incentive Structures 00:44:22 What Morningstar Medalist Ratings Signal for Semiliquid Funds More From Morningstar Morningstar's Guide to Public/Private Investing Private Equity Funds Step Into the Spotlight Private Credit Pricing: Are Prosecutors Opening Up Pandora's Box? If you have a comment or a guest idea, please email us at TheLongView@Morningstar.com. Follow Christine Benz (@christine_benz) and Ben Johnson (@MstarBenJohnson) on X, and Christine Benz, Amy Arnott, and Ben Johnson on LinkedIn. Visit Morningstar.com for new research and insights from Christine, Ben, and Amy. Subscribe to Christine's weekly newsletter, Improving Your Finances. If you want more Morningstar podcasts, check out The Morning Filter and Investing Insights. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan Mail◆ What now for European Secured Notes ater long-awaited debut?◆ The mood in European securitization amid MFS fallout and reg reform ◆ Digitalisation of bond market is up to the regulatorsBpifrance achieved a world first this week, pricing the inaugural European Secured Note. The deal was a success but it has taken about a decade to get the product from concept to market. The question is now where next for ESNs? This twist on a covered bond has clear applications as a capital market instrument that can help fund the real economy but it could be argued that its future lies in the hands of the regulators and how they choose to treat it. We discuss the different paths ESNs might be led down and the alternatives open to issuers.Meanwhile, GlobalCapital's European securitization team is back from Global ABS in Barcelona — that market's major gathering for the year. We find out what is giving the market cause for fear and cheer. We discuss how specialist lenders, banks and funds are adjusting to prevent or mitigate another scandal like the one that befell Market Financial Solutions earlier this year, and how the securitization market feels about the direction of regulatory reform.Sticking with the topic of all-powerful financial regulators, we also discuss why it is they rather than the technologists that will decide the fate of bond market digitialisation.Now read on:ESNs arrive: regulatory recognition may follow French firstEuropean Secured Notes needn't rush to BrusselsFunds eye ABF market share as banks pull backABS conference delegates emit mixed feelings of trepidation and optimismOn DLT, regulators could bring order — or disruption

Mfs around here and surround areas I swear

Michael Tannenbaum became CEO of Figure in early 2024, taking over from founder Mike Cagney and leading the company through its September 2025 IPO. In this conversation, we get into the mechanics of how Figure's blockchain-based platform competes with Fannie Mae and Freddie Mac, what it actually takes to cut mortgage origination costs from $12,000 to $1,000, and where the real opportunities in tokenization lie.What We CoveredTaking over as CEO from Mike Cagney and the Big Rocks frameworkHow Figure describes itself: building the future of capital markets on blockchainThe B2B partner network and how it compares to Fannie Mae's functionCutting mortgage origination costs from $12,000 to $1,000 and 45 days to fiveWhy Figure competes directly with Fannie Mae and Freddie MacHow blockchain eliminates third-party diligence and prevents loan double-pledgingThe Figure Connect marketplace and its rapid growth since June 2024Where tokenization adds real value — and where it doesn'tYLDS: Figure's SEC-registered yield-bearing stablecoin and its role in capital marketsThe timing and mechanics of Figure's September 2025 IPOBuilding a rate-agnostic business across different macro environmentsThree growth areas: consumer mortgages, Democratized Prime, and on-chain equitiesKey TakeawaysFigure's origination platform and its capital market are the same system — you can't separate them, and that's the competitive moat. Tokenization only creates liquidity when the underlying assets are standardized and fungible; putting unique assets on a blockchain doesn't conjure buyers. The recent fraud cases involving double-pledged loans (Tricolor, First Brands, MFS) have turned blockchain's immutability from a skeptic's objection into a selling point. And Figure is running at what Michael calls the rule of 150 — 100% year-over-year growth at 50% margins — in one of the most rate-sensitive and entrenched markets on earth.About Michael TannenbaumMichael Tannenbaum is the CEO of Figure, a blockchain-based capital markets company he took public on Nasdaq in September 2025. Before Figure, he was an early executive at both SoFi (Chief Revenue Officer) and Brex (COO), and sat on the Brex board when it was acquired by Capital One. He began his career in investment banking at J.P. Morgan.Connect with Fintech One-on-One:Tweet me @PeterRentonConnect with me on LinkedInFind previous Fintech One-on-One episodes

As part of 401(k) Specialist's Q2 Deep Dive on target-date funds, Editor-in-Chief Brian Anderson sits down with Mercer Director of Defined Contribution Strategic Research Teams Preet Prashar to discuss the rapidly evolving TDF landscape—from market concentration and glidepath design to passive investing, fiduciary concerns, lifetime income solutions, and private assets.Drawing from Mercer's recent white paper, “Target Date Landscape: The Evolution of Target Date Strategies and Future Considerations,” Prashar shares key insights plan sponsors and advisors should consider as target-date funds continue to dominate the defined contribution marketplace.SEE ALSO:• $4.8 Trillion and Growing: Why Traditional TDFs are Still Key to 401(k) Success• Executive Q&A: Refining Accumulation Strategies Through TDFs with MFS' Jeri Savage

Marc Rubinstein joins Excess Returns to explain what private credit, bank earnings, insurance balance sheets, fintech growth, and arbitrage firms reveal about the modern financial system. The conversation covers why private credit risks may not be systemic in the traditional banking-crisis sense, but still matter for investors because of redemption gates, hidden leverage, opaque structures, incentive conflicts, and correlations that can spike when markets are under stress.Marc Rubinstein on Xhttps://x.com/MarcRubyNet Interesthttps://www.netinterest.co/In this episode, we discuss:Why the Fed says private credit redemption risks are limited and manageableWhat Blue Owl's redemption gates reveal about private credit liquidityHow post-2008 bank regulation pushed risk into private credit, hedge funds, trading firms, and exchangesWhy banks and private credit firms are both competitors and collaboratorsThe “layer cake” of leverage connecting banks, private credit, and borrowersHow HSBC's loss tied to Atlas and MFS highlights hidden credit risksWhy insurance companies have become increasingly tied to private creditWhy rapid growth can be dangerous in financial businessesWhat bank earnings show about the gap between weak consumer confidence and resilient spendingWhy post-mortem reports from SVB, Credit Suisse, and other failures reveal what investors could not see in real timeHow Revolut became one of the most interesting fintech stories in global bankingWhy Marc calls this a potential golden age of arbitrageWhat Jane Street, public BDC discounts, private asset valuations, and geopolitical fragmentation tell us about market structureWhy investors may still be too anchored to the 2008 banking playbookWhere Marc sees risk and opportunity in financials, banks, Europe, and non-bank financial institutionsTimestamps:00:00 Private credit, hidden risks, and correlation spikes05:03 Why Blue Owl became a private credit warning sign10:20 How private credit grew after the 2008 financial crisis15:30 Banks and private credit as financial “frenemies”19:44 HSBC, Atlas, MFS, and the layer cake of leverage24:11 Apollo, Athene, insurance assets, and private credit incentives29:20 Why higher rates have not broken more of the financial system33:40 Bank earnings, consumer confidence, and resilient spending37:20 Why “I don't know” can be a powerful signal from bank CEOs41:46 Revolut and the ambition to build a truly global bank47:38 Why growth can be dangerous in finance52:19 Private assets, public BDC discounts, and arbitrage opportunities56:34 What investors misunderstand about banks today59:31 How Marc would think about financials as a long-short investor

Redaktøren og rektoren har debattert MFs sjel i kristenpressen de siste ukene. Nå møtes de for å oppsummere debatten. Selbekk kommer med Imam-profeti. Hosted on Acast. See acast.com/privacy for more information.

En Capital Intereconomía seguimos la apertura del Ibex 35 y de las principales bolsas europeas en una sesión marcada por referencias macro y movimientos corporativos relevantes. La jornada arranca con el análisis del dato de la Encuesta de Población Activa (EPA) junto a Valentín Bote, director de Randstad Research, que ayuda a tomar el pulso al mercado laboral español en un contexto económico exigente. En el análisis de mercados, Pablo García, director de Divacons-Alphavalue, destaca que el oro cae a mínimos de tres semanas, reflejando la atención del mercado en las conversaciones entre EE.UU. e Irán y en las decisiones de los bancos centrales. En el plano empresarial, sobresalen los resultados de compañías como BP, que duplica beneficios, o Eni, que acelera su actividad en refino. En contraste, Barclays cae en bolsa tras provisionar pérdidas vinculadas a la quiebra de MFS. En el sector tecnológico, destaca el acuerdo de Google (Alphabet) con el Departamento de Defensa de Estados Unidos para el uso de inteligencia artificial en proyectos gubernamentales, lo que refuerza el papel estratégico de la IA. Además, se pone en valor el avance de Corea del Sur, cuya bolsa se convierte en uno de los mayores mercados del mundo impulsada por la tecnología. Terminamos la hora con el consultorio de bolsa junto a Juan Ignacio Marrón, donde se responden las dudas de los oyentes en un entorno de mercado condicionado por la geopolítica y la macroeconomía.

Defense budgets are on the rise, but where is the money going and what does it mean for investors? In this episode, Sean Kenney and Elizabeth McGuire describe how global defense spending is shifting from cyclical discretion into strategic necessity, focusing on how the money is being spent, why long-term earnings visibility is improving, and what new entrants mean for assessing valuations in the sector. Listen in for expert insights to help you understand the rapidly evolving defense sector and what it means for portfolios.   Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited.; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.;  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800.  This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. All investments involve risks, including market fluctuation and investors may lose the principal amount invested. Investors should obtain and read the prospectus and/or document set forth in Article 37-3 of Financial Instruments and Exchange Act carefully before making the investments. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM). In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa - This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa.

Dan Caruso, Managing Director, Caruso Ventures; Founding CEO of Zayo Group Dan Caruso built Zayo from a startup into an $8.5B bandwidth infrastructure platform through 45 acquisitions. In Part 1, he walks through the full buyer-led playbook — how the thesis was built on a contrarian bet that everyone else got wrong, how proprietary deals were sourced through early relationship-building, and why fast integration wasn't a reputation problem — it was a competitive advantage.  He also breaks down the metric trap most roll-up operators fall into: mistaking EBITDA growth for true value creation. If your board is tracking acquisitions individually or your deal structure is loaded with earnouts, this conversation will challenge how you're running the program. What you'll learn: How to identify and build a contrarian acquisition thesis with investor alignment Why proprietary deal flow is a brand and relationship problem, not a sourcing problem How Zayo executed an unsolicited, fully funded offer on a larger public company — and won Why tracking individual acquisitions kills synergies in a roll-up When earnouts hurt more than they help — and what to use instead How clean, all-cash offers win on certainty, not price Dan's approach to thesis validation, investor alignment, and platform value creation is documented in the Roll-Up Readiness Assessment inside the Intelligence Hub, a stage-gated guide built directly from this conversation. Access inside the Intelligence Hub — → Access inside the M&A Science Hub — members only. This episode of M&A Science is presented by DealRoom. DealRoom just automated Pipeline Management with AI so you can spend less time updating deals, and more time working them. Automatically push deal context from Outlook to DealRoom Pipeline and use AI to keep deal target data and tasks updated, so follow-ups never slip through the cracks. No manual logging. No stale pipeline data. See for yourself: https://hubs.ly/Q045fXp50 ____________________ Episode Chapters [00:02:00] Introduction: Dan Caruso and the Zayo Story [00:03:51] Background: From Ma Bell to MFS to Level Three [00:08:58] Lessons from WorldCom: What Fake Value Creation Looks Like [00:10:35] What First-Time Acquirers Get Wrong [00:12:39] Building the Zayo Thesis: Fiber Orphans and Accidental Owners [00:17:20] Raising Capital When You Have a Track Record [00:23:50] What Must Be True for the Thesis to Work [00:26:54] Why EBITDA Doesn't Measure Value Creation [00:29:15] The Danger of Tracking Acquisitions Individually [00:31:17] What Actually Drove Zayo's Success [00:36:10] Convincing Sellers: Proprietary Sourcing and Relationship Strategy [00:45:30] The Above Net Acquisition: Unsolicited, Fully Funded, at a Conference [00:51:02] Negotiation Tactics: Unpredictability, Silence, and Team Play [01:02:16] Deal Structure: Why Zayo Avoided Earnouts [01:03:56] Clean Cash Offers and Certainty of Close

Matt sits down with Piero De Luca, the man behind Mad Fabricators Society. They cover hot rodding in the early 2000's, the start of Mad Fab, and much more. Piero inspired Matt to start Iron Trap and Live Wire was on of the many channeled Model A's Matt used for reference when building the Pagoda City Coupe! Be sure to follow Piero and MFS on all social media linked below!!Subscribe on YouTube - https://www.youtube.com/@MADFABRICATORSTVFollow on Instagram - https://www.instagram.com/mad_fabricators/Check out our website!! - www.irontrapgarage.comDon't forget to listen to our weekly podcast!! - https://open.spotify.com/show/09WnyHe97uUrMkeXF6dQIL?si=dObfWrBKTyqP42qwrO5vjw- Get 10% Off Your Eastwood Order With The Coupon Code ITG10 At Checkout * Some Products Excluded -  https://glnk.io/73rnx/irontrap  Wanna send us something?Iron Trap GaragePO Box 6New Berlinville, PA19545Matt's Instagram - @irontrap - https://www.instagram.com/irontrap/Mike's Instagram - @mhammsteak - https://www.instagram.com/mhammsteak/Iron Trap Parts Instagram - @irontrapfinds - https://www.instagram.com/irontrapfinds/Iron Trap eBay - https://www.ebay.com/usr/irontrapgarage/

The collapse of UK mortgage bridge lender Market Financial Solutions has caused chaos across specialist lending. Mortgages are the heart of the securitised products business, and if you can't trust mortgages, what can you rely on?9fin broke the news of double pledging and shortfall in collateral found under its warehouse facilities. The fraud allegations are reminiscent of the recent cases of First Brands and Tricolor in the US that have shaken the private asset-based lending industry.Lots of well-known firms have been caught on the wrong side of MFS — the likes of Barclays, Atlas SP and Castlelake — and it was a close shave for other lenders.In this episode of Distressed Diaries, host and senior reporter Bianca Boorer sits down with 9fin asset-based finance editor Owen Sanderson and Kawai Chung, mortgage market veteran and CEO of UK lender Folk2Folk, to dig into the drama, assess the impact, and consider how the ‘safest' form of lending might have ended up in double-pledging.Most importantly, we look at what could be done differently in future — as borrowers scramble to prove their credentials and lenders look over their books, what's the future of asset-based finance in Europe?

MFS, a big lender based in London, has been making risky loans and is in the British equivalent of bankruptcy. Now, investors are buying up U.S. government bonds, and lenders are pulling back from the riskiest parts of the private credit markets. Is there a bigger pattern here? We'll discuss. Then, Anthropic is rejecting the Pentagon's demands for unrestricted use of its technology, and we'll hear how business is going for a Main lobster fisherman.

MFS, a big lender based in London, has been making risky loans and is in the British equivalent of bankruptcy. Now, investors are buying up U.S. government bonds, and lenders are pulling back from the riskiest parts of the private credit markets. Is there a bigger pattern here? We'll discuss. Then, Anthropic is rejecting the Pentagon's demands for unrestricted use of its technology, and we'll hear how business is going for a Main lobster fisherman.

Hyperscalers are spending, but when will this capex help companies to improve returns? In this episode, Sean Kenney sits down with guests Erica Zieba and John Haddad to delve into the massive capex expansion in 2026, focusing on the underlying funding arrangements and, ultimately, generating returns. They also share examples on how equity and fixed income investors are working together to understand what it means across the capital structure and sectors. Listen in for unique insights to help you identify opportunities as well as warning flags.   Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited.; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.;  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800.  This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. All investments involve risks, including market fluctuation and investors may lose the principal amount invested. Investors should obtain and read the prospectus and/or document set forth in Article 37-3 of Financial Instruments and Exchange Act carefully before making the investments. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM). In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa - This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa.

Send us a textNolan Lynch, an external covering California, joins today's episode. We cover:The training programs we learned as internals at fund companies MFS, PGIM, and NatixisStructures to deliver an impactful fund pitch to advisorsChallenging advisors asset class allocation and consulting them on product optionsInterested in working with Internal Use Only to sharpen your pitch skills or create a framework/ training program for your internals or new hires?DM us on Instagram or email us internaluseonlypodcast@gmail.comSupport the show

Every other Friday, I co-host another film podcast, The Midnight Film Society, and each year Damian and I rank our favorite films. Enjoy our best of 2025 here as a bonus episode and subscribe to MFS to get more current film discussions, including next week's episode on our most anticipated films of 2026!Listen to MFS on ⁠Apple⁠, ⁠Spotify⁠, or wherever you get your podcasts!For more info head to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠underratedmoviepodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/UnderratedMoviePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/underratedmoviepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@underratedmoviepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCAbpTHWyBle7yKJv4-gR_g⁠⁠

Jamie is having a comically bad month and the news is grim. Please indulge the Party Girls in a chill, lowkey episode where they examine a number of human interest stories, including: the meaning of Christmas, the Pisces Co-worker, the anti-sharing movement, MFs getting tattoos under anesthesia, and Jamie's page on Canary Mission, which links to her Onlyfans. They also read and reply to some listener comments for their new "mailbag" segment and say a few words about Asad Haider. Emerge Presents: Asad Haider on Communist Politics In Our Time (2021): https://www.youtube.com/watch?v=n9-jFFQwnJg Thank you to everyone who donated to help fund Frida Gato's two(!) emergency surgeries. All of Jamie's money later, she seems to be recovering nicely. Venmo: @jamie-peck, paypal: jamie.e.peck@gmail.com, cashapp: JamiePeck666. Buy the book: https://store.illwilleditions.com/products/depose-luigi-mangione-and-the-right-to-health SIGN UP NOW at https://patreon.com/partygirls to get all of our bonus content, Discord access, and a shout out on the pod! Follow us on ALL the Socials: Instagram: @party.girls.pod TikTok: @party.girls.pod Twitter: @partygirlspod BlueSky: @partygirls.bsky.social Leave us a nice review on Apple Podcasts or Spotify if you feel so inclined: https://podcasts.apple.com/us/podcast/party-girls/id1577239978 https://open.spotify.com/show/71ESqg33NRlEPmDxjbg4rO Executive Producer: Andrew Callaway Producers: Ryan M., Jon B

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

It's growth investing, just not as we knew it. Technology is disrupting the traditional signals for growth companies, such as revenue acceleration or addressable market expansion. In this episode, Sean Kenney sits down with MFS portfolio manager Brad Mak to explore what the AI revolution means for the future of growth companies and the potential for bubbles. They also cover current opportunities underappreciated by the market and look forward to what 2026 has in store. Listen in for the signals to help you identify where growth investing is heading.         Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited.; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.;  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800.  This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. All investments involve risks, including market fluctuation and investors may lose the principal amount invested. Investors should obtain and read the prospectus and/or document set forth in Article 37-3 of Financial Instruments and Exchange Act carefully before making the investments. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM). In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa - This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa.  

Pilar Gomez-Bravo is Co-Chief Investment Officer fixed income and portfolio manager at MFS Investment Management. She was previously a managing director at Neuberger Berman, and prior to that, spent a significant amount of her career at Lehman Brothers.Our conversation starts with Pilar's childhood which saw her move around a lot with her family - this forced an adaptability and resilience that served her well when her career in finance took many unexpected turns. Market and segment volatility played a notable supporting role in Pilar's early career, most particularly with a massive setback when Lehman Brothers collapsed and again when she joined a start-up hedge fund for a short period of time. MFS represented another change of direction, but ended up as a very fertile one, as she steadily progressed through the ranks there until ultimately co-leading the fixed income function in her current role. We discuss what makes an employer a positive influence, and how a nurturing work setting can bring out the best in teams.Finally we reflect on what it is to have a full life, and the importance of staying diversified in life as well as in work.Series 5 of 2025 is kindly sponsored by Diamond Hill. Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. An independent active asset manager with significant employee ownership, Diamond Hill's investment strategies include differentiated US and non-US equity, alternative long-short equity and fixed income.

Learn how to save on Thanksgiving dinner and decide if filing taxes jointly makes sense for common law couples. How can you trim your Thanksgiving costs without skimping on the feast? Should common law spouses file taxes jointly or separately? Hosts Sean Pyles and Elizabeth Ayoola dig into tax choices for couples to help you understand which filing status may fit your situation and what to weigh before you commit. But first, Anna Helhoski joins Elizabeth to unpack why the cost of a classic Thanksgiving dinner is down this year and how to shop smart for the expanded table. They cover where prices fell and rose across the holiday menu, what turkey deals and meal bundles at places like Aldi, Walmart and Target could mean for your budget, and why recently reduced food tariffs may take time to show up on store shelves. Then, tax Nerd Bella Avila joins Sean and Elizabeth to answer a listener's question about common law marriage and taxes. They discuss when married filing jointly versus separately can lower your bill, how IRS rules treat common law marriages (and what to consider if you move states), and practical to-dos like updating your W-4 within 10 days, timing a name change, and reviewing credit and student loan implications. They also touch on cohabitation agreements (a “prenup” for common law couples) and why clear money conversations matter before you file. Want us to review your budget? Fill out this form — completely anonymously if you want — and we might feature your budget in a future segment! https://docs.google.com/forms/d/e/1FAIpQLScK53yAufsc4v5UpghhVfxtk2MoyooHzlSIRBnRxUPl3hKBig/viewform?usp=header In their conversation, the Nerds discuss: common law marriage, file taxes jointly common law, married filing jointly vs separately, Thanksgiving dinner cost 2025, turkey prices 2025, food inflation CPI, Aldi Thanksgiving meal, Walmart Thanksgiving meal, Target Thanksgiving bundle, Whole Foods Thanksgiving dinner price, Harry and David Thanksgiving meal, save money on Thanksgiving, store brand vs name brand, frozen vegetables price, sweet potato shortage North Carolina, avian flu turkey prices, food tariffs 2025, Trump food tariff rollback, grocery prices outlook, head of household vs single, surviving spouse filing status, education credits married filing separately, child tax credit MFS rules, medical expense deduction 7.5% AGI, W-4 update after marriage, add domestic partner to health insurance, dependent eligibility common law spouse, IRS rules common law marriage, cohabitation agreement, prenup cost and timeline, name change and taxes, tax brackets married vs single, standard deduction married filing jointly, and credit and deductions phaseouts joint filers. To send the Nerds your money questions, call or text the Nerd hotline at 901-730-6373 or email podcast@nerdwallet.com. Like what you hear? Please leave us a review and tell a friend. Learn more about your ad choices. Visit megaphone.fm/adchoices

Power, not oil, is where the action is. Electrification trends, boosted by AI, are accelerating the growth of the traditionally flat power sector. In this episode, Sean Kenney sits down with MFS portfolio manager Jude Jason to decode what's really driving power demand, where the bottlenecks are and how investors can navigate the messy middle of the energy transition. They also reveal three durable lanes presenting attractive investment opportunities today and map out how the energy sector may evolve in the years ahead. Listen in for signals to help you cut through the hype and stay ahead.

From Taylor Swift's ultimate fangirl moment to Victoria Beckham’s headline-making confessions and a happy MAFS surprise.... today's Morning Tea is piping hot.☕ Taylor Swift proves she’s just like us — fangirling hard over AJ from the Backstreet Boys ☕ Kevin Federline continues his press tour (and oversharing) about Britney☕ Victoria Beckham addresses that long-rumoured affair on Call Her Daddy ☕ And MAFS golden couple Martha and Michael have baby news! Once you’ve devoured this morning’s celeb stories, get your daily news headlines from The Quicky here. THE END BITS Support independent women's media Follow us on TikTok, Instagram and Facebook. And subscribe to our Youtube channel. Read all the latest entertainment news on Mamamia... here. Discover more Mamamia Podcasts here. CREDITS Host & Producer: Ash London Executive Producer: Monisha IswaranBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Was geschah hinter den Kulissen der Ereignisse, die als "friedliche Revolution" in die Geschichte eingingen? Wieso blieb es friedlich? Zeitzeugen – auch aus dem Sicherheitsapparat – sprechen teils erstmals Klartext.

The software sector is evolving fast—and not always in ways investors expect. From the rise of AI-native startups to the shifting economics of SaaS, the rules of the game are being rewritten. In this episode, Sean Kenney sits down with MFS software analyst Matt Doherty to unpack what really drives long-term winners in software. They explore how to think about moats in a world of falling barriers to entry, why valuation is more art than science in this sector, and how AI is both a disruptor and an accelerant. Whether you're wondering if SaaS is dead or just trying to make sense of the next wave of innovation, this conversation will help you cut through the noise and invest with clarity.   The views expressed are those of the speaker and are subject to change at any time. These views are for informational purposes only and should not be relied on as a recommendation to purchase any security or as an offer of securities or investment advice. No forecast can be guaranteed. Past performance is no guarantee of future results.   Unless otherwise indicated, logos and product and service names are trademarks of MFS® and its affiliates and may be registered in certain countries. Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC.; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited. No securities commission or similar regulatory authority in Canada has reviewed this communication; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM) and Bahrain readers. In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa: This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa. This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance.   66259.1

This podcast is the audio version of the Gear Garage Live Show, where we answer submitted questions and talk all things whitewater. Today's Show! Rescue Courses Just Get a Kayak Answer Questions Some of the Questions that Zach covered in the Q&A section of this episode Topic: Deadhead I got invited on MFS trip for September 3rd this year, and the group that invited me is planning to deadhead the first 25 then picking up people/gear at Indian Creek. The trip leader told me I have to pack light. But I feel that I can easily make it down the upper 25 with a fully loaded boat as I've done it before 1 year ago after the blowout at Velvet and Hells Half Mile. What do you think about this? Topic: Low Water MF Hey Zach, Heading down the Middle Fork of the Salmon on Sept 7th for 6 days. 4 of us in IKs, packing light. How do you think IKs will do in the top 25 miles? Looks like we'll be at 1.5 feet or close. P.S. Are there any small group adventures off the beaten path you've been wanting to explore? Thanks for all the info you have provided on this river! Your recent videos are very helpful. Topic: Pushing vs Pulling & Loaded Boats on Private Trips Hey Zach- First question... I've seen several of your videos about pushing vs pulling, but I was curious about your deadheading MFS trip review video. It seems like the general consensus is to push, unless you need to set up for something. Have some of your other recommendations been to pull as much as possible, especially for newer rowers, or heavy gear boats? Or is this a situationally dependent scenario. Second question... On our recent trip to the Main Salmon this year, we had 1 - 18 foot cat boat, 2 - 14 foot round boats, and my 16 foot round boat. I was the heaviest boat by far. I wasn't worried about the weight and low water correlation on that section. How do you balance the creature comforts of a really comfy trip in low water (like below 2 feet on MFS) and the main necessities in this scenario. Thanks for taking time to answer questions during your busy time of year! Topic: Raft Recommendation I am looking for a boat recommendation that would be good for rowing day runs like the Clack or White Salmon (would love to row the Wind sometime) and could be used for light 1 or 2 night trips with a passenger. I was wanting your take on length as well as models. I have looked at the Sotar ST and SL and wanted to know if you had a preference for rowing more technical whitewater. Hope your season is going well and I appreciate all the things I have learned from this channel. Topic: Clean Water Storage Zach, hope the season has been great for NWRC. I saw this new product from Lifestraw and wanted your opinion. It's a 5-gallon pressurized water filtration system It seems like it could replace everyone bringing water jugs. It's good for 4700 gallons for one cartridge and can take straight river water. It looks a little bigger than a 5 gallon bucket, but if every boat in a group has 5-10 gallons of water, this could replace a lot of jugs on a trip. Thanks for your show and videos and have a great day,

​In this special compilation episode of The Nine, we're bringing you bite-sized insights from live Nicsa events, featuring expert voices on three of the industry's most talked-about topics.Mike De​m​bro (MFS) puts political noise in perspective with a data-driven look at investing through election cyclesJoanne Kane (​S​S&C) delivers a plainspoken, no-nonsense breakdown of what firms need to know about managing AI riskTimothy Pitney (TIAA) highlights why longevity literacy is just as essential as financial literacy when planning for retirementThese clips are pulled directly from Nicsa's marquee forums and webinars—bringing real-time intelligence to your headphones in nine minutes or less.More at http://nicsa.org/podcasts

In this episode, we delve into the intersection of AI and pharma, uncovering how artificial intelligence is set to change drug discovery and its impact on investing. Learn what this means for the future of healthcare and your investment portfolio.   Disclosure: The views expressed are those of the speaker and are subject to change at any time. These views are for informational purposes only and should not be relied on as a recommendation to purchase any security or as an offer of securities or investment advice. No forecast can be guaranteed. Past performance is no guarantee of future results.   Unless otherwise indicated, logos and product and service names are trademarks of MFS® and its affiliates and may be registered in certain countries. Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC.; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited. No securities commission or similar regulatory authority in Canada has reviewed this communication; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM) and Bahrain readers. In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa: This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa. This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. 65116

FUCKWIT gubmnt agency gives a car to every 15 workers ■ Childproofing destroys America ■ Gubmnt now regulates how you crap! ■ “MFs” wreck your life ■ Why stop/start motors, trigger locks, and lo-flo toilets suck ■ “CHAIR HEIGHT toilets / why you should SMASH them!

We ride today with author and musician Michael Farris Smith. This is a spirited ride with a Southern gentleman, who explores the grit and challenges that lead one to change, and possible redemption. Our ride with MFS was recorded just before the release of his eighth novel, Lay Your Armor Down—and just after his directorial […]

Guests are way back. In this episode, I sit down with my best—Chase Lambin is a former professional baseball player who spent 15 years chasing the Big League dream, and now coaches in the Texas Rangers organization.Chase gives us an inside peak at life in professional baseball, including stories I've never heard before. His Tracy McGrady story alone makes this episode worth tuning in.We get into my favorite part of having a buddy who coaches future Major Leaguers—the emotional aspect of players getting called up to the Big Leagues. For me, seeing a text vid of a call-up is like looking into my stocking on Christmas morning. If you're not still doing that, might be time to upgrade your S/O (but that's for a future solo ep).Chase tells the story of their most recent call-up, Blaine Crim, who, incidentally, is my new favorite player.Funny how you get older and pull for the 27-year old call-up you have some Kevin Bacon connection to. But when you were 9, you'd have used that rookie's baseball card in your tire spokes. Well, I'm older now, and would sooner use a Topps Justin Verlander to give my 4-year old's balance bike the vroom sound.We also discuss Chase's approach to parenting, coaching and maintaining perspective. He shares insights from his book The Hitters Handbook, and reflects on lessons learned from coaches and teammates throughout his career.Re baseball, we cover everything from 12-year old travel ball to Corey Seager riling up the Rangers in the playoffs because he got excited about a homerun (which he doesn't do often).There's a reason Chase & I have remained the best of buds since we met in 1994. Episodes where I have him on keep getting better!But yeah, that's not the reason.I'll just tell you that having a 'bestie' you've known since 9th grade, and getting to broadcast some our conversations with you beautiful MFs, is one of my great joys in life. At least in part, because you've told me you enjoy them too.

RHOBH cast rumors continue to circulate with rumored firings, downgrades and one beloved "friend of” being asked to hand in her diamond and exit the building. Teresa is up to her old tricks with half truths, lies and not accurately remembering the past as it actually happened. Our recent live show has come and gone and you shady MFs have asked questioned that we would rather not have answered, but as promised, no pleading the 5th so we, well, mentioned it all. Today, we share these questions and our answers asked by you, our beloved audience. From past pods we got tangled up in, past Housewife feuds, which Bravolebs were awful behind the scenes off air during our past interviews, the “sources” of where we get our confidential info, how to fix Bravo from its current state of disarray and last, but way to bury the lead not least, one very angered, outraged Kelly Dodd. @behindvelvetrope @davidyontef Learn more about your ad choices. Visit megaphone.fm/adchoices

Send a textEp 270 Sean Sherk Early Years Sean Sherk has one of the most unique journeys to becoming a UFC World Champion. His departure from the sport has always been somewhat of a mystery; in this interview we discuss his path to being called World Champion. It is a powerful listen Ep 270 Sean Sherk Early years 0:00 plugs/ promotions 0:42 Lytes out intro 1:14 Joey Venti's guest introduction1:39 interview start 2:08 departure from fighting 4:43 wrestling career 10:22 Jiu Jitsu match with Chris Brennan 11:47 dealings with Brad Kohler 14:26 Travis Wiuff 16:13 Sean Sherk vs Roscoe Ostyn19:10 training with Greg Nelson 22:28 Frank Shamrock not in UFC hall of fame23:26 Midwest mma Championship tournament 25:26 Extreme Challenge 2828:08 Sean Sherk vs Karo Parisyan33:09 Sean Sherk vs Karo Parisyan rematch 34:09 fighting with a full time job37:14 wrestling in high school 39:17 choosing to persue fighting 40:41 chasing the highs in life 43:38 getting the call from the UFC 46:50 getting the nick name “Juggernaut”47:40 Sean Sherk vs Tiki Goshen48:47 Sean Sherk vs Manny Gamburyan52:04 training with Matt Hughes 52:34 choosing not to train at MFS 54:10 getting into street fights 55:49 Sean Sherk vs Marty Armendarez1:00:48 training ground and pound 1:04:03 training partner Tom Schmitz1:05:05 Clint Class 1:06:09 Damian Hertz 1:07:04 cancelled bout with Jutaro Nakao1:09:47 Sean Sherk vs Curtis Brigham1:11:07 Sean Sherk vs Kiuma Kunioku1:17:38 Sean Sherk vs Claudionor Da Silva Fontinelle1:22:25 getting back into the UFC 1:27:12 Sean Sherk vs Jutaro Nakao1:28:33 Sean Sherk vs Benji Radach1:32:53 Sean Sherk vs John Alexander1:34:50 overcoming adversity 1:35:56 Sean Sherk vs Matt Hughes 1:38:13 getting cut from the UFC 1:40:11 retiring from fighting 1:44:07 co owning training mask 1:46:40 life after fighting 1:52:06 interview wrap up 1:53:37 outro/ closing thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@MMAHistoryPodcastDiscord:https://discord.gg/s3mV6wyNgvSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris Lytle - Founder/Owner - @chrislightsoutlytle Mike Davis - MMA Detective - @mikedavis632 Joey Venti - Assistant - @aj_ventitreTyson Green - Producer - @ty.green.weldingAndrew Mendoza - Timestamps - @ambidexstressAndy Campbell - Social Media Manager - @martial_mindset_Josh Campbell - ContributerJohn Perretti - Historical ContributerOutro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FightPodcastSupport the show

Send us a textEp 270 Sean Sherk Early Years Sean Sherk has one of the most unique journeys to becoming a UFC World Champion. His departure from the sport has always been somewhat of a mystery; in this interview we discuss his path to being called World Champion. It is a powerful listen Ep 270 Sean Sherk Early years 0:00 plugs/ promotions 0:42 Lytes out intro 1:14 Joey Venti's guest introduction1:39 interview start 2:08 departure from fighting 4:43 wrestling career 10:22 Jiu Jitsu match with Chris Brennan 11:47 dealings with Brad Kohler 14:26 Travis Wiuff 16:13 Sean Sherk vs Roscoe Ostyn19:10 training with Greg Nelson 22:28 Frank Shamrock not in UFC hall of fame23:26 Midwest mma Championship tournament 25:26 Extreme Challenge 2828:08 Sean Sherk vs Karo Parisyan33:09 Sean Sherk vs Karo Parisyan rematch 34:09 fighting with a full time job37:14 wrestling in high school 39:17 choosing to persue fighting 40:41 chasing the highs in life 43:38 getting the call from the UFC 46:50 getting the nick name “Juggernaut”47:40 Sean Sherk vs Tiki Goshen48:47 Sean Sherk vs Manny Gamburyan52:04 training with Matt Hughes 52:34 choosing not to train at MFS 54:10 getting into street fights 55:49 Sean Sherk vs Marty Armendarez1:00:48 training ground and pound 1:04:03 training partner Tom Schmitz1:05:05 Clint Class 1:06:09 Damian Hertz 1:07:04 cancelled bout with Jutaro Nakao1:09:47 Sean Sherk vs Curtis Brigham1:11:07 Sean Sherk vs Kiuma Kunioku1:17:38 Sean Sherk vs Claudionor Da Silva Fontinelle1:22:25 getting back into the UFC 1:27:12 Sean Sherk vs Jutaro Nakao1:28:33 Sean Sherk vs Benji Radach1:32:53 Sean Sherk vs John Alexander1:34:50 overcoming adversity 1:35:56 Sean Sherk vs Matt Hughes 1:38:13 getting cut from the UFC 1:40:11 retiring from fighting 1:44:07 co owning training mask 1:46:40 life after fighting 1:52:06 interview wrap up 1:53:37 outro/ closing thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@MMAHistoryPodcastDiscord:https://discord.gg/s3mV6wyNgvSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris Lytle - Founder/Owner - @chrislightsoutlytle Mike Davis - MMA Detective - @mikedavis632 Joey Venti - Assistant - @aj_ventitreTyson Green - Producer - @ty.green.weldingAndrew Mendoza - Timestamps - @ambidexstressAndy Campbell - Social Media Manager - @martial_mindset_Josh Campbell - ContributerJohn Perretti - Historical ContributerOutro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FightPodcastSupport the show

In this episode, we look at creatine. We'll discuss the positive effects on the body and the brain, bust a few myths, and explain why it's great for everyone: old or young, male or female, active or sedentary. The optimal amount of daily creatine is very difficult to reach through food on a regular basis, so supplementation is ideal in this scenario.Contact Mike:Mike Sinopoli - NASM Certified Nutrition CoachInstagram, Facebook, X, LinkedIn: @mfswellnessemail: mike@mfswellness.comphone: 630-361-4907www.mfswellness.com 

ETFs have taken over the world, or at least that's what you'd believe if you spent any time reading financial media in the US. Passive investing! Low costs! No fund manager egos! And of course, that looming prediction: “ETFs will destroy price discovery!” But in India? Crickets. While ETFs have become mainstream in the US, with trillions of dollars flowing into passive investing strategies, India's ETF story is still unfolding. Why haven't ETFs exploded in India despite our obsession with stocks? And more importantly, should you be investing in ETFs or mutual funds? In this episode, Deepak and Shray get into the weeds on all things Exchange Traded Funds — what they are, how they work, where they don't work, and why, despite sounding like the next great revolution in investing, they haven't quite clicked here yet. 00:00:00 - Introduction 00:02:01 - How big are ETFs? 00:07:30 - Why are ETFs so successful in the US 00:09:42 - How do ETFs work? 00:13:52 - Isn't it better to move into ETFs then? 00:16:01 - Who are you buying the ETF from? 00:20:08 - Are there any advantages in ETFs over MFs in India? 00:25:10 - What role do Market Makers play in ETFs? 00:30:12 - When and why do ETF prices trade above their NAV? 00:39:14 - Role of liquidity in ETF prices 00:42:06 - Why don't people do SIPs into ETFs and Stocks? 00:48:44 - How are ETFs useful for investors? 00:53:17 - What about Commodity ETFs? 00:55:47 - What about Liquid ETFs? 00:59:52 - How do regulations like stock-lending and free-float impact ETF returns? 01:04:53 - What are Deepak's thoughts about Active ETFs? 01:07:06 - Will ETFs gain market share from Mutual Funds?

MFS, which pioneered the first mutual fund in 1924, recently entered the ETF arena with the launch of five actively managed products.  MFS's Emily Dupre discusses the firm's decision-making process around launching ETFs, their investment capabilities, and the role active...

Send a textEp 261 Al Iaquinta BEFORE the UFCAl Iaquinta had an impressive career within the UFC that included a world title fight; what most people dont know is how crazy and difficult his path was to getting a UFC contract.This interview has Iaquinta recaling stories and issues prior to his stint within the UFC that have never talked aboutSpecial thank you to Nick Lamagna and the A Game podcast for lining this interview up 0:00 plugs/ promotions 0:42 Lytes out intro 1:22 interview start4:30 refusing to attend fighter summit 6:23 not getting paid fight bonuses9:55 getting knee surgery 16:35 relationship with NickNickNick  19:26 attending UFC 53 22:29 learning Jiu Jitsu off DVDs early on 23:40 training at a MFS gym 25:11 meeting Bryce Mitchell 27:31 Al Iaquinta vs Greg LaChaga29:14 promoter Ed Hsu 33:18 fighting event in Mexico 35:41 Al Iaquinta vs Mike Prokop37:19 Al Iaquinta vs Mike Bennett39:50 Al Iaquinta vs Nick Maurielo41:13 Al Iaquinta vs Will Martinez44:12 getting fights from Andrew Montanez47:21 sparring sessions at Miletech fighting systems 50:13 Cancelled bout with Drew Dober53:14 training at Renzo Gracie's gym 57:10 Al Iaquinta vs Mervin Rodriguez57:31 dealings with Lou Neglia 58:50 Al Iaquinta vs Will Martinez1:01:07 Al Iaquinta vs Tim Sylvester1:03:15 Al Iaquinta vs Gabriel Migioli1:10:05 Al Iaquinta vs Pat Audinwood1:13:04 trying out for TUF 1:16:02 experience on TUF show 1:21:35 picked first by Urijah Faber1:23:00 Al Iaquinta vs Myles Jury1:24:27 TUF highlights 1:26:19 Al Iaquinta vs Michael Chiesa1:27:30 Aljamain Sterling and Floyd Mayweather issues1:29:18 thoughts on Douglas Crosby 1:32:40 turning away movie role 1:33:53 interview wrap up 1:34:51 outro/closing thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressAndy - Social Media Manager - @martial_mindset_Outro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FightPodcastSupport the show

Send us a textEp 261 Al Iaquinta BEFORE the UFCAl Iaquinta had an impressive career within the UFC that included a world title fight; what most people dont know is how crazy and difficult his path was to getting a UFC contract.This interview has Iaquinta recaling stories and issues prior to his stint within the UFC that have never talked aboutSpecial thank you to Nick Lamagna and the A Game podcast for lining this interview up 0:00 plugs/ promotions 0:42 Lytes out intro 1:22 interview start4:30 refusing to attend fighter summit 6:23 not getting paid fight bonuses9:55 getting knee surgery 16:35 relationship with NickNickNick  19:26 attending UFC 53 22:29 learning Jiu Jitsu off DVDs early on 23:40 training at a MFS gym 25:11 meeting Bryce Mitchell 27:31 Al Iaquinta vs Greg LaChaga29:14 promoter Ed Hsu 33:18 fighting event in Mexico 35:41 Al Iaquinta vs Mike Prokop37:19 Al Iaquinta vs Mike Bennett39:50 Al Iaquinta vs Nick Maurielo41:13 Al Iaquinta vs Will Martinez44:12 getting fights from Andrew Montanez47:21 sparring sessions at Miletech fighting systems 50:13 Cancelled bout with Drew Dober53:14 training at Renzo Gracie's gym 57:10 Al Iaquinta vs Mervin Rodriguez57:31 dealings with Lou Neglia 58:50 Al Iaquinta vs Will Martinez1:01:07 Al Iaquinta vs Tim Sylvester1:03:15 Al Iaquinta vs Gabriel Migioli1:10:05 Al Iaquinta vs Pat Audinwood1:13:04 trying out for TUF 1:16:02 experience on TUF show 1:21:35 picked first by Urijah Faber1:23:00 Al Iaquinta vs Myles Jury1:24:27 TUF highlights 1:26:19 Al Iaquinta vs Michael Chiesa1:27:30 Aljamain Sterling and Floyd Mayweather issues1:29:18 thoughts on Douglas Crosby 1:32:40 turning away movie role 1:33:53 interview wrap up 1:34:51 outro/closing thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressAndy - Social Media Manager - @martial_mindset_Outro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FightPodcastSupport the show

951: In this episode of Technovation, Peter High interviews Dan Caruso, founder of Zayo Group and Caruso Ventures. Dan, a pioneer in communications infrastructure, shares his journey from leading multi-billion dollar exits with MFS and Level 3 to his current investments in quantum and space technologies. He discusses insights from his new book Bandwidth: The Untold Story of Ambition, Deception, and Innovation That Shaped the Internet Age.

Rob Almeida and Genevieve Gilroy, consumer staples sector leader, explore the shifting dynamics in the consumer staples sector in this podcast episode. They also discuss the importance of a collaborative, global research platform with differentiating opportunities across categories and companies.   Chapters: 00:00 - 01:59 Setting the Stage 01:59 - 05:26 Role of a Sector Leader 05:26 - 06:40 Traditional Draws to Consumer Staples 06:40 - 10:14 Agents of Change and Lower Barriers to Entry 10:14 - 11:47 Innovation and the Landscape of Work 11:47 - 14:58 GLP-1s as a Driver of Risk and Opportunity 14:58 - 16:35 Compelling Categories 16:35 - 18:57 Understanding the Rising Price Environment 18:57 - END Consumer Staples in Summary   This material is intended for investment professional use only and not intended for retail investors.   The views expressed are those of the speaker and are subject to change at any time. These views are for informational purposes only and should not be relied upon as a recommendation to purchase any security, or as an offer of securities or investment advice. No forecast can be guaranteed. Past performance is no guarantee of future results.   Please keep in mind that a sustainable investing approach does not guarantee positive results and all investments, including those that integrate ESG considerations into the investment process, carry a certain amount of risk including the possible loss of the principal amount invested.   Distributed by:  U.S. – MFS Institutional Advisors, Inc., MFS Investment Management and MFS Fund Distributors, Inc.; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited. Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International Limited, a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.  Note to Europe readers: Issued in Europe by MFS Investment Management S.à r.l. – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800.  This material shall not be circulated or distributed to any person other than to professional investors and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd.; Australia/New Zealand - MFS International Australia Pty Ltd holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International Limited, a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission. MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance.; For Professional Investors in China – MFS Financial Management Consulting Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. All investments involve risks, including market fluctuation and investors may lose the principal amount invested. Investors should obtain and read the prospectus and/or document set forth in Article 37-3 of Financial Instruments and Exchange Act carefully before making the investments.   Unless otherwise indicated, logos, product and services names are trademarks of MFS and its affiliates and may be registered in certain countries.

How has a writer known principally for his contained domestic novels come to represent the most dynamic elements of world literature? In Kazuo Ishiguro Against World Literature (Bloomsbury, 2025), Chris Holmes expands our understanding of how world literature engages with the most pressing crises of the 20th and 21st centuries by examining Ishiguro's fascination with characters who are profoundly constrained in their ability to understand global systems to which they are subject. Rather than following the established pattern of so-called global novels, which crisscross the planet exhibiting a knowing cosmopolitanism, Ishiguro's fictional engagement with the world comes principally in the form of characters who are cut off from the global systems that abuse them. By examining the ways in which Ishiguro foregrounds the in-process thinking of those who fail to comprehend their place in the flow of politics, culture, and ideas, Holmes positions Ishiguro as the great chronicler of everyday lives, and as such, prepares a mode of reading world literature that questions the assumptions for how we live and think with others when each of us is deeply limited. Chris Holmes is Associate Professor and Chair of Literatures in English at Ithaca College. He is the host of the literary interview podcast, Burned by Books, and he is host and co-producer on Novel Dialogue, the podcast of the Society of Novel Studies, both of which are New Books Network partners. His most recent essays appear in NOVEL, MFS, Critique, and Public Books. Caroline Levine is David and Kathleen Ryan Professor of the Humanities at Cornell University. She is the author most recently of The Activist Humanist: Form and Method in the Climate Crisis, and Forms: Whole, Rhythm, Hierarchy, Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

How has a writer known principally for his contained domestic novels come to represent the most dynamic elements of world literature? In Kazuo Ishiguro Against World Literature (Bloomsbury, 2025), Chris Holmes expands our understanding of how world literature engages with the most pressing crises of the 20th and 21st centuries by examining Ishiguro's fascination with characters who are profoundly constrained in their ability to understand global systems to which they are subject. Rather than following the established pattern of so-called global novels, which crisscross the planet exhibiting a knowing cosmopolitanism, Ishiguro's fictional engagement with the world comes principally in the form of characters who are cut off from the global systems that abuse them. By examining the ways in which Ishiguro foregrounds the in-process thinking of those who fail to comprehend their place in the flow of politics, culture, and ideas, Holmes positions Ishiguro as the great chronicler of everyday lives, and as such, prepares a mode of reading world literature that questions the assumptions for how we live and think with others when each of us is deeply limited. Chris Holmes is Associate Professor and Chair of Literatures in English at Ithaca College. He is the host of the literary interview podcast, Burned by Books, and he is host and co-producer on Novel Dialogue, the podcast of the Society of Novel Studies, both of which are New Books Network partners. His most recent essays appear in NOVEL, MFS, Critique, and Public Books. Caroline Levine is David and Kathleen Ryan Professor of the Humanities at Cornell University. She is the author most recently of The Activist Humanist: Form and Method in the Climate Crisis, and Forms: Whole, Rhythm, Hierarchy, Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

How has a writer known principally for his contained domestic novels come to represent the most dynamic elements of world literature? In Kazuo Ishiguro Against World Literature (Bloomsbury, 2025), Chris Holmes expands our understanding of how world literature engages with the most pressing crises of the 20th and 21st centuries by examining Ishiguro's fascination with characters who are profoundly constrained in their ability to understand global systems to which they are subject. Rather than following the established pattern of so-called global novels, which crisscross the planet exhibiting a knowing cosmopolitanism, Ishiguro's fictional engagement with the world comes principally in the form of characters who are cut off from the global systems that abuse them. By examining the ways in which Ishiguro foregrounds the in-process thinking of those who fail to comprehend their place in the flow of politics, culture, and ideas, Holmes positions Ishiguro as the great chronicler of everyday lives, and as such, prepares a mode of reading world literature that questions the assumptions for how we live and think with others when each of us is deeply limited. Chris Holmes is Associate Professor and Chair of Literatures in English at Ithaca College. He is the host of the literary interview podcast, Burned by Books, and he is host and co-producer on Novel Dialogue, the podcast of the Society of Novel Studies, both of which are New Books Network partners. His most recent essays appear in NOVEL, MFS, Critique, and Public Books. Caroline Levine is David and Kathleen Ryan Professor of the Humanities at Cornell University. She is the author most recently of The Activist Humanist: Form and Method in the Climate Crisis, and Forms: Whole, Rhythm, Hierarchy, Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

The Mexican Firing Squad is a bonafide tequila-based classic with almost 100 years' history — despite what its '70s-disco-era-sounding name suggests. As James O'Donnell, bar manager at Fives Bar in New Orleans, puts it, the MFS is a great recommendation for those looking to riff on the Spicy Margarita. But it's also so much more than that. Listen on (or read below) to discover James' Mexican Firing Squad recipe — and don't forget to like, review, and subscribe!James O'Donnell's Mexican Firing Squad Recipe Ingredients - 4-5 dashes Angostura bitters- ¾ ounce fresh lime juice- ¾ ounce Hibiscus grenadine (1:1 Pom juice to sugar + 5-7 grams dried hibiscus per quart)- 2 dashes Árbol Chile tincture (Blanco tequila and Chile de árbol)- 2 ounces reposado tequila, such as Patrón- Garnish: dehydrated lime wheelDirections 1. Add all ingredients to a cocktail shaker with ice.2. Hard shake until well chilled and strain into a Rocks glass filled with cubed ice.3. Garnish with a dehydrated lime wheel.

Every other Monday I co-host another film podcast, The Midnight Film Society, and this week we looked back at 2024. Damian and I count down our top 10 films from last year. Listen to MFS on Apple, Spotify, or wherever you get your podcasts! For more info head to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠underratedmoviepodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/UnderratedMoviePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/underratedmoviepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@underratedmoviepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCAbpTHWyBle7yKJv4-gR_g⁠⁠

Could your tax filing status save you thousands on student loan payments? You're about to find out. We're discussing how choosing to file jointly or separately can impact your student loan repayment strategy. You'll hear about real-world scenarios, from high-income couples evaluating their tax implications to the strategic benefits of filing separately in community property states. Plus, we'll explore how recent legislative scrutiny on loan repayment plans could affect your financial planning.    From navigating recertification dates to leveraging tax extensions, you'll gain practical insights that could reshape the way you manage your taxes and student loans.   Key moments:   05:18 Should a dual-dentist household file taxes separately? A real case study 18:00 Myths vs. reality of tax filing extensions  22:13 How filing taxes separately changes everything in a community property state  26:42 A physician-teacher couple cashes in on the breadwinner loophole 35:31 Reclaim your money by amending your MFS tax return   Like the show? There are several ways you can help! Follow on Apple Podcasts, Spotify or Amazon Music Leave an honest review on Apple Podcasts  Subscribe to the newsletter Feeling helpless when it comes to your student loans? Try our free student loan calculator Check out our refinancing bonuses we negotiated Book your custom student loan plan Get profession-specific financial planning   Do you have a question about student loans? Leave us a voicemail here or email us at help@studentloanplanner.com and we might feature it in an upcoming show!  

Send a textEp 244 Miletich Fighting Systems  Championship Years - Jeremy Horn Pat Miletich, Matt Hughes, Jens Pulver and Tim Sylvia captured the UFC championship belts while all working out at the Miletich Fighting System in Davenport Iowa. Jeremy Horn was the architect and master planner behind the work that went into this incredible moment in mixed martial arts. Jeremy Horn and the MMA set Mike Davis discuss this historic championship run while also examining the science that went into each fight. Ep 244 Miletich Fighting Systems  Championship Years - Jeremy Horn 0:00 Lytes out intro0:19 guest introduction0:57 interview start 0:59 making the switch to Miletich fighting systems 2:14 reason for the move to MFS 4:33 deciding to make fighting a career 7:49 Matt Hughes and Pat Miletich friendship 9:34 realizing Miletich fighting systems was special 11:33 cornering Pat Miletich at UFC 16 14:53 Jeremy Horn vs Frank Shamrock 22:53 giving Vitor Belfort a pep talk. 23:11 payment issues with the IFC24:34 training in Montreal25:42 cornering Mark Coleman 29:59 Amaury Bitetti training Pat Miletech32:49 Jens Pulver early days at MFS35:57 Robbie Lawler at MFS38:05 Carlos Newton vs Pat Miletich 40:00 Matt Hughes vs Dennis Hallman 41:45 handling a loss 42:42 Jens Pulver winning lightweight title 43:28 Manager Monte Cox 47:42 Jens Pulver vs BJ Penn 48:31 Carlos Newton vs Matt Hughes 49:26 Matt Hughes vs Hayato Sakurai 50:50 UFC not wanting Pat Miletich 51:59 Robbie Lawler vs Aaron Riley 52:25 Matt Hughes vs Carlos Newton “rematch” 53:19 Matchmaker Joe Silva 54:12 Tim Sylvia vs Ricco Rodriguez 55:18 Matt Hughes vs Sean Sherk56:34 first thoughts on Tim Sylvia 59:27 Matt Hughes vs BJ Penn 1:01:27 Frank Mir vs Tim Sylvia “arm break” 1:03:32 Tim Sylvia cut from the UFC 1:04:11 Andre Arlovski 1:05:04 MFS winning multiple titles 1:06:01 Tim Sylvia vs Fedor Emelianenko 1:07:22 experience with Don Frye 1:08:47 Rulon Gardner 1:09:43 BJ Penn callout rumor 1:09:56 choking out Promoter Chad Mason 1:10:37 thoughts on Miletich fighting systems era 1:15:09 reason for never reffing fights 1:15:48 realizing it was time to leave Iowa 1:18:39 50 fight club members 1:21:08 fighters not being able to move on after career 1:22:17 interview wrap up 1:22:41 outro/ final thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressAndy - Social Media Manager - @martial_mindset_Outro song: Power - https://tunetank.com/t/2gji/1458-power#miletichfightingsystems #jenspulver#timsylvia#patmiletich#matthughes#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FighSupport the show

Ep 244 Miletich Fighting Systems  Championship Years - Jeremy Horn Pat Miletich, Matt Hughes, Jens Pulver and Tim Sylvia captured the UFC championship belts while all working out at the Miletich Fighting System in Davenport Iowa. Jeremy Horn was the architect and master planner behind the work that went into this incredible moment in mixed martial arts. Jeremy Horn and the MMA set Mike Davis discuss this historic championship run while also examining the science that went into each fight. Ep 244 Miletich Fighting Systems  Championship Years - Jeremy Horn 0:00 Lytes out intro0:19 guest introduction0:57 interview start 0:59 making the switch to Miletich fighting systems 2:14 reason for the move to MFS 4:33 deciding to make fighting a career 7:49 Matt Hughes and Pat Miletich friendship 9:34 realizing Miletich fighting systems was special 11:33 cornering Pat Miletich at UFC 16 14:53 Jeremy Horn vs Frank Shamrock 22:53 giving Vitor Belfort a pep talk. 23:11 payment issues with the IFC24:34 training in Montreal25:42 cornering Mark Coleman 29:59 Amaury Bitetti training Pat Miletech32:49 Jens Pulver early days at MFS35:57 Robbie Lawler at MFS38:05 Carlos Newton vs Pat Miletich 40:00 Matt Hughes vs Dennis Hallman 41:45 handling a loss 42:42 Jens Pulver winning lightweight title 43:28 Manager Monte Cox 47:42 Jens Pulver vs BJ Penn 48:31 Carlos Newton vs Matt Hughes 49:26 Matt Hughes vs Hayato Sakurai 50:50 UFC not wanting Pat Miletich 51:59 Robbie Lawler vs Aaron Riley 52:25 Matt Hughes vs Carlos Newton “rematch” 53:19 Matchmaker Joe Silva 54:12 Tim Sylvia vs Ricco Rodriguez 55:18 Matt Hughes vs Sean Sherk56:34 first thoughts on Tim Sylvia 59:27 Matt Hughes vs BJ Penn 1:01:27 Frank Mir vs Tim Sylvia “arm break” 1:03:32 Tim Sylvia cut from the UFC 1:04:11 Andre Arlovski 1:05:04 MFS winning multiple titles 1:06:01 Tim Sylvia vs Fedor Emelianenko 1:07:22 experience with Don Frye 1:08:47 Rulon Gardner 1:09:43 BJ Penn callout rumor 1:09:56 choking out Promoter Chad Mason 1:10:37 thoughts on Miletich fighting systems era 1:15:09 reason for never reffing fights 1:15:48 realizing it was time to leave Iowa 1:18:39 50 fight club members 1:21:08 fighters not being able to move on after career 1:22:17 interview wrap up 1:22:41 outro/ final thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressAndy - Social Media Manager - @martial_mindset_Outro song: Power - https://tunetank.com/t/2gji/1458-power#miletichfightingsystems #jenspulver#timsylvia#patmiletich#matthughes#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FighSupport the show